Deals In Depth: December 2020
Executive Summary
Merck KGaA and Artios penned a global three-year strategic research collaboration to discover and develop multiple precision oncology drugs. The deal could be worth close to $7bn for four-year-old Artios. AstraZeneca announced a definitive agreement to acquire public rare disease drug developer Alexion for approximately $39bn. This was 2020’s largest M&A. Financing reached $28bn in biopharma, $879m in device, and $2.4bn in diagnostics.